Nellie Byun1, 2, Ayan Ghoshal, 13, Nathaniel D. Kelm2, 4, Robert L. Barry2, 5, Wellington Pham2, 5, Carrie K. Jones1, 3, John C. Gore2, 5, P. Jeffrey Conn1, 3
1Vanderbilt Center for Neuroscience Drug Discovery, Nashville, TN, United States; 2Vanderbilt University Institute of Imaging Science, Nashville, TN, United States; 3Pharmacology, Vanderbilt University Medical Center, Nashville, TN, United States; 4Biomedical Engineering, Vanderbilt University, Nashville, TN, United States; 5Radiology & Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN, United States
Previous preclinical studies have demonstrated the potential of compounds that target the metabotropic glutamate receptor subtype 5 (mGluR5) for the treatment of schizophrenia. Like typical and atypical antipsychotic drugs, the novel selective mGluR5 potentiator VU0360172 suppressed amphetamine-induced hyperlocomotion in rodents. Here we used VU0360172 and pharmacologic MRI (phMRI) to determine specific regions of mGluR5-mediated modulation of amphetamine-induced brain activation as well as the effects of VU0360172 alone.